WorldCat Identities

Giralt, Jordi

Overview
Works: 9 works in 9 publications in 3 languages and 13 library holdings
Roles: Other, Author, Contributor
Publication Timeline
.
Most widely held works by Jordi Giralt
New targets for tumor radiosensitization by Jordi Giralt( )

1 edition published in 2002 in English and held by 2 WorldCat member libraries worldwide

Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients by On behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR)( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients by on behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR)( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Tratamiento del cáncer de mama diagnosticado durante el embarazo by Cristina Saura Manich( )

1 edition published in 2017 in Spanish and held by 1 WorldCat member library worldwide

El cáncer de mama diagnosticado durante el embarazo es una entidad poco frecuente. Aún así, disponemos de datos en la literatura que avalan la seguridad del tratamiento de estas pacientes teniendo en cuenta que este debe ser lo más parecido posible a una mujer no embarazada y que debe realizarse en centros especializados que aseguren el manejo multidisciplinar con el objetivo de minimizar complicaciones obstétricas y pediátricas. Se puede realizar cirugía de la mama y la axila en cualquier momento del embarazo, tratamiento con quimioterapia basada en antraciclinas y/o taxanos a partir del segundo trimestre y se debe evitar el uso de la radioterapia y fármacos biológicos en estas pacientes a lo largo de todo el embarazo siempre que esto sea posible. En esta tesis doctoral se recoge el tratamiento realizado a 49 mujeres diagnosticadas de cáncer de mama durante su embarazo en el Hospital Vall d'Hebrón o remitidas a este centro para su tratamiento. Se reportan datos en cuanto a las características de la población materna y fetal, su pronóstico, el tratamiento realizado a las pacientes y las complicaciones derivadas del mismo. Además, se comunican datos de seguimiento específico cardiológico tanto en las madres como en los fetos y datos de seguimiento del desarrollo neuropsicológico en los neonatos expuestos a quimioterapia intrautero. Por último, se ha realizado un estudio de factores angiogénicos maternos valorado mediante la ratio sFlt-1/PIGF y la influencia de estos sobre el desarrollo placentario en la población tratada con quimioterapia. El objetivo es que esta ratio ya usada en población de mujeres embarazadas no expuestas a quimioterapia, pueda ser informativa en el futuro a la hora de la toma de decisiones cercanas al momento del parto también en esta población. Una ratio de sFlt-1/PIGF>38 debería sugerir en la práctica clínica aumentar el seguimiento obstétrico de estas pacientes por la potencial aparición de complicaciones relacionadas con la insuficiencia placentaria así como a valorar a partir de la semana 34 la posibilidad de indicar el parto y en cambio, una valor normal en la ratio sFlt-1/PIGF, debería evitar la precipitación en la decisión de adelantar el parto en esta población
Rol de la inserció profilàctica de catèters balons oclusius percutanis a pacients amb anomalia placentària adherent by Mireia Teixidor i Viñas( )

1 edition published in 2017 in Catalan and held by 1 WorldCat member library worldwide

Objectiu: La malaltia adherent placentària (MAP) és una causa d'hemorràgia postpart severa, amb una pèrdua sanguínia esperada de 3-5L. Ha estat tractada amb cesària i histerectomia peri- part de forma tradicional. S'exposa la nostra experiència amb la inserció profilàctica de catèters balons oclusius percutanis (CBOP) a ambdues artèries ilíaques internes, amb o sense necessitat d'embolització arterial uterina per tal de preservar l'úter de la pacient. Durant el treball de recerca s'ha desenvolupat un nou protocol de tractament conservador multidisciplinar anomenat Triple P procedure. S'avalua els resultats obtinguts des de la implantació d'aquest protocol, així com la necessitat de intervencions futures a dones amb MAP. Material i Mètode: Dos articles han estat publicats a la literatura. El primer va ser publicat al Clinical radiology i inclou vint- i- set pacients diagnosticats perinatalment de MAP amb sospita de placenta percreta que varen ser tractades amb CBOP immediatament abans de realitzar un part per cesària. El segon article és un estudi de cohorts publicat al Ultrasound in Obstetrics and Gynecology on es compara 19 dones amb MAP tractades amb el Triple-P protocol (Grup estudi) i 11 tractades amb CBOP i part per cesària (Grup Control). El nombre i volum de transfusions sanguínies, pèrdua sanguínia estimada, la necessitat d'embolització arterial uterina (EAU) i/o la necessitat d'histerectomia han estat recopilades a ambdós articles. Resultats: Placenta percreta va ser confirmada en 19 pacients [sis (54.5%) pacients del Grup Control i 13 (68.4%) del Grup Estudi]. La pèrdua sanguínia mitja estimada va ser menor al Grup Estudi que en el Grup Control (1.70 L vs 2.17 L, respectivament), però la diferència no va ser estadísticament significativa (P=0.445). El risc d'hemorràgia postpart (HPP) i la necessitat d'histerectomia van disminuir de forma estadísticament significativa en el Grup Estudi (HPP, 54.5% vs 15.8%; P=0.035; histerectomia, 27.3% vs 0.0%; P=0.045). Com a conseqüència, es va observar una disminució estadísticament significativa en l'estada hospitalària de les pacients del Grup estudi (P=0.044). Conclusió: Els CBOP amb o sense EAU contribueixen a la disminució de la pèrdua sanguínia i del risc d'histerectomia peripart a les pacients amb MAP. La introducció del Triple-P procedure disminueix de forma significativa el risc d'histerectomia, HPP i estada hospitalària a aquestes pacients
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial( )

1 edition published in 2015 in English and held by 1 WorldCat member library worldwide

Background Panitumumab is a fully human monoclonal antibody that targets EGFR. We aimed to compare chemoradiotherapy plus panitumumab with chemoradiotherapy alone in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck. Methods In this international, open-label, randomised, controlled, phase 2 trial, we recruited patients with locally advanced squamous-cell carcinoma of the head and neck from 41 sites in nine countries worldwide. Patients aged 18 years and older with stage III, IVa, or IVb, previously untreated, measurable (≥10 mm for at least one dimension), locally advanced squamous-cell carcinoma of the head and neck (non-nasopharygeal) and an Eastern Cooperative Oncology Group performance status of 0-1 were randomly assigned (2:3) by an independent vendor to open-label chemoradiotherapy (three cycles of cisplatin 100 mg/m2) or panitumumab plus chemoradiotherapy (three cycles of intravenous panitumumab 9·0 mg/kg every 3 weeks plus cisplatin 75 mg/m2) using stratified randomisation with a block size of five. All patients received 70 Gy to gross tumour and 50 Gy to areas at risk for subclinical disease with standard fractionation. The primary endpoint was local-regional control at 2 years, analysed in all randomised patients who received at least one dose of their assigned protocol-specific treatment (chemotherapy, radiation, or panitumumab). The trial is closed and this is the final analysis. This trial is registered with ClinicalTrials.gov, number NCT00500760. Findings Between Oct 26, 2007, and March 26, 2009, 153 patients were enrolled and 150 received treatment (63 in the chemoradiotherapy group and 87 in the panitumumab plus chemoradiotherapy group). Local-regional control at 2 years was 68% (95% CI 54-78) in the chemoradiotherapy group and 61% (50-71) in the panitumumab plus chemoradiotherapy group. The most frequent grade 3-4 adverse events were dysphagia (17 [27%] of 63 patients in the chemoradiotherapy group vs 35 [40%] of 87 in the panitumumab plus chemoradiotherapy group), mucosal inflammation (15 [24%] vs 48 [55%]), and radiation skin injury (eight [13%] vs 27 [31%]). Serious adverse events were reported in 20 (32%) of 63 patients in the chemoradiotherapy group and in 37 (43%) of 87 patients in the panitumumab plus chemoradiotherapy group. Interpretation In patients with locally advanced squamous-cell carcinoma of the head and neck, the addition of panitumumab to standard fractionation radiotherapy and cisplatin did not confer any benefit, and the role of EGFR inhibition in these patients needs to be reassessed. Funding Amgen
P16, HPV, and Cetuximab: What Is the Evidence?( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Abstract: Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer worldwide. It has recently been appreciated that human papillomavirus (HPV) status (or p16 status, which is a frequently used surrogate for HPV status) is prognostic for oropharyngeal SCCHN. Here, we review and contextualize existing p16 and HPV data, focusing on the cetuximab registration trials in previously untreated, locoregionally advanced, nonmetastatic SCCHN (LA SCCHN) and in recurrent and/or metastatic SCCHN (R/M SCCHN): the IMCL-9815 and EXTREME clinical trials, respectively. Taken together, the available data suggest that, while p16 and HPV are prognostic biomarkers in patients with LA SCCHN and R/M SCCHN, it could not be shown that they are predictive for the outcomes of the described cetuximab-containing trial regimens. Consequently, although HPV status provides prognostic information, it is not shown to predict therapy response, and so is not helpful for assigning first-line therapy in patients with SCCHN. In addition, we discuss assays currently used to assess p16 and HPV status, as well as the differentiation between these two biomarkers. Ultimately, we believe HPV E6/E7 polymerase chain reaction-based mRNA testing may represent the most informative technique for assessing HPV status in patients with SCCHN. While p16 is a valid surrogate for HPV status in oropharyngeal carcinoma (OPC), there is a higher risk of discordance between p16 and HPV status in non-OPC SCCHN. Collectively, these discussions hold key implications for the clinical management of SCCHN. Implications for Practice: Human papillomavirus (HPV) status (or its commonly utilized surrogate p16) is a known prognostic biomarker in oropharyngeal squamous-cell carcinoma of the head and neck (SCCHN). We evaluated implications of the available evidence, including cetuximab registration trials in previously untreated locoregionally advanced (LA) SCCHN and recurrent and/or metastatic (R/M) SCCHN. We conclude that, although p16 and HPV are prognostic biomarkers for both LA and R/M SCCHN, they have not been shown to be predictive of response to the described cetuximab-containing regimens for either indication. Thus, current evidence suggests that benefits of cetuximab are observed in both p16-/HPV-positive and -negative SCCHN. Abstract : This study reviews available methodologies for evaluating human papillomavirus (HPV) status, as well as current evidence involving the prognostic and potential predictive value of p16 and HPV status in patients with locoregionally advanced or recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab combination regimens, with an emphasis placed on recent subgroup analyses of the phase III IMCL-9815 and EXTREME trials
Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial( )

1 edition published in 2015 in English and held by 1 WorldCat member library worldwide

Background We aimed to compare panitumumab, a fully human monoclonal antibody against EGFR, plus radiotherapy with chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck. Methods In this international, open-label, randomised, controlled, phase 2 trial, we recruited patients with locally advanced squamous-cell carcinoma of the head and neck from 22 sites in eight countries worldwide. Patients aged 18 years and older with stage III, IVa, or IVb, previously untreated, measurable (≥10 mm for at least one dimension), locally advanced squamous-cell carcinoma of the head and neck (non-nasopharygeal) and an Eastern Cooperative Oncology Group performance status of 0-1 were randomly assigned (2:3) by an independent vendor to open-label chemoradiotherapy (two cycles of cisplatin 100 mg/m2 during radiotherapy) or to radiotherapy plus panitumumab (three cycles of panitumumab 9 mg/kg every 3 weeks administered with radiotherapy) using a stratified randomisation with a block size of five. All patients received 70-72 Gy to gross tumour and 54 Gy to areas of subclinical disease with accelerated fractionation radiotherapy. The primary endpoint was local-regional control at 2 years, analysed in all randomly assigned patients who received at least one dose of their assigned protocol-specific treatment (chemotherapy, radiation, or panitumumab). The trial is closed and this is the final analysis. This study is registered with ClinicalTrials.gov, number NCT00547157. Findings Between Nov 30, 2007, and Nov 16, 2009, 152 patients were enrolled, and 151 received treatment (61 in the chemoradiotherapy group and 90 in the radiotherapy plus panitumumab group). Local-regional control at 2 years was 61% (95% CI 47-72) in the chemoradiotherapy group and 51% (40-62) in the radiotherapy plus panitumumab group. The most frequent grade 3-4 adverse events were mucosal inflammation (25 [40%] of 62 patients in the chemoradiotherapy group vs 37 [42%] of 89 patients in the radiotherapy plus panitumumab group), dysphagia (20 [32%] vs 36 [40%]), and radiation skin injury (seven [11%] vs 21 [24%]). Serious adverse events were reported in 25 (40%) of 62 patients in the chemoradiotherapy group and in 30 (34%) of 89 patients in the radiotherapy plus panitumumab group. Interpretation Panitumumab cannot replace cisplatin in the combined treatment with radiotherapy for unresected stage III-IVb squamous-cell carcinoma of the head and neck, and the role of EGFR inhibition in locally advanced squamous-cell carcinoma of the head and neck needs to be reassessed. Funding Amgen
 
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.95 (from 0.88 for Chemoradio ... to 0.99 for Tratamient ...)

Languages